The Hidden Cost of Inconsistent Denial Workflows in PE-Backed Healthcare Platforms

Denial Management as an Integration Problem, Not Just a Billing Problem

Private equity-backed healthcare platforms live and die on integration execution. EHR consolidation, coding standardization, and revenue cycle centralization all get real attention in the first 100 days post-close. Denial appeal workflow rarely does — it tends to be treated as a downstream billing detail rather than a distinct integration workstream, which is exactly why it quietly erodes value.

Every add-on acquisition brings its own denial handling habits, and without deliberate standardization, those habits don't converge toward the platform's best practice — they drift toward whatever's easiest for each individual practice's remaining staff, which is often no formal process at all.

The EBITDA Math Nobody Puts in the Deal Model

Denial rates across healthcare run meaningfully into double digits industry-wide, and a substantial share of denied claims are never appealed at all — not because they were undeniable, but because nobody owned the process. For a platform generating meaningful annual claim volume, even a modest improvement in the percentage of denials that get appealed, combined with a modest improvement in appeal-to-payment rate, translates into a real and recurring EBITDA impact — the kind of recurring, structural improvement that's directly relevant to exit multiple, not just a one-time cleanup.

The inverse is also true and less often discussed: platforms that let denial handling degrade during integration are quietly giving back margin every quarter, in a way that's hard to see in monthly financials because it shows up as revenue that was never collected rather than an expense that was incurred.

Why Add-On Acquisitions Compound the Problem

A platform's first few acquisitions might get individual attention on billing integration. By acquisition ten or twenty, the operating team is stretched, and denial workflow standardization is one of the first things to get deprioritized in favor of higher-visibility integration work like EHR migration or provider compensation harmonization.

This is precisely backwards from a value-creation standpoint. EHR migration is visible, disruptive, and expensive to get wrong. Denial workflow standardization is invisible, low-disruption, and cheap to get wrong — which is exactly why it tends to get ignored until someone finally asks why the portfolio's aggregate collection rate hasn't improved despite scale.

Building Denial Consistency Into the Integration Playbook

Treating denial management as a formal workstream means assigning it explicit ownership at the platform RCM level, setting a standard timeline for bringing a new acquisition onto the shared process (commonly within the first 60 to 90 days), and tracking denial and appeal metrics as part of the standard post-close integration dashboard alongside EHR conversion and coding compliance.

What Operating Partners Should Ask in Diligence

Before close, it's worth asking a target practice directly: what percentage of denials get appealed, what's the appeal-to-payment rate, and how is that tracked? Vague or unavailable answers are themselves diagnostic — they usually mean the practice is leaving money on the table today, and that the platform will inherit that gap unless it's addressed deliberately during integration rather than assumed away.